Robert S Kerbel
#85,332
Most Influential Person Now
Researcher
Robert S Kerbel's AcademicInfluence.com Rankings
Robert S Kerbellaw Degrees
Law
#1362
World Rank
#1723
Historical Rank
Common Law
#26
World Rank
#29
Historical Rank
International Law
#134
World Rank
#194
Historical Rank
Download Badge
Law
Why Is Robert S Kerbel Influential?
(Suggest an Edit or Addition)Robert S Kerbel's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Angiogenesis as a therapeutic target (2005) (2533)
- Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis. (2009) (1763)
- Clinical translation of angiogenesis inhibitors (2002) (1581)
- The anti-angiogenic basis of metronomic chemotherapy (2004) (1348)
- Tumor angiogenesis: past, present and the near future. (2000) (1007)
- Establishment and characterization of first trimester human trophoblast cells with extended lifespan. (1993) (947)
- Beta 1-6 branching of Asn-linked oligosaccharides is directly associated with metastasis. (1987) (897)
- Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. (1997) (897)
- Mutant ras oncogenes upregulate VEGF/VPF expression: implications for induction and inhibition of tumor angiogenesis. (1995) (836)
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. (2000) (774)
- Antiangiogenic therapy: impact on invasion, disease progression, and metastasis (2011) (645)
- Endothelial expression of autocrine VEGF upon the uptake of tumor-derived microvesicles containing oncogenic EGFR (2009) (620)
- Antiangiogenic therapy in oncology: current status and future directions (2016) (603)
- Therapy-Induced Acute Recruitment of Circulating Endothelial Progenitor Cells to Tumors (2006) (595)
- The multifaceted circulating endothelial cell in cancer: towards marker and target identification (2006) (593)
- Acquired resistance to the antitumor effect of epidermal growth factor receptor-blocking antibodies in vivo: a role for altered tumor angiogenesis. (2001) (559)
- Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity (2000) (557)
- Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. (2003) (480)
- E-Cadherin–dependent Growth Suppression is Mediated by the Cyclin-dependent Kinase Inhibitor p27KIP1 (1998) (477)
- Antiangiogenic Therapy: A Universal Chemosensitization Strategy for Cancer? (2006) (468)
- A role for survivin in chemoresistance of endothelial cells mediated by VEGF (2002) (468)
- Inhibition of tumor angiogenesis as a strategy to circumvent acquired resistance to anti‐cancer therapeutic agents (1991) (467)
- Effect of p53 Status on Tumor Response to Antiangiogenic Therapy (2002) (466)
- Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. (2002) (460)
- Rapid chemotherapy-induced acute endothelial progenitor cell mobilization: implications for antiangiogenic drugs as chemosensitizing agents. (2008) (445)
- Thrombospondin 1, a mediator of the antiangiogenic effects of low-dose metronomic chemotherapy (2003) (413)
- Anticancer therapies combining antiangiogenic and tumor cell cytotoxic effects reduce the tumor stem-like cell fraction in glioma xenograft tumors. (2007) (398)
- Multiple circulating proangiogenic factors induced by sunitinib malate are tumor-independent and correlate with antitumor efficacy (2007) (390)
- A cancer therapy resistant to resistance (1997) (384)
- Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells. (1999) (374)
- Consensus guidelines for the use and interpretation of angiogenesis assays (2018) (370)
- Genetic heterogeneity of the vasculogenic phenotype parallels angiogenesis; Implications for cellular surrogate marker analysis of antiangiogenesis. (2005) (360)
- Impact of the cyclin–dependent kinase inhibitor p27Kip1 on resistance of tumor cells to anticancer agents (1996) (355)
- Mouse models of advanced spontaneous metastasis for experimental therapeutics (2011) (353)
- Glioma tumor stem-like cells promote tumor angiogenesis and vasculogenesis via vascular endothelial growth factor and stromal-derived factor 1. (2009) (348)
- Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa (2018) (339)
- Human Tumor Xenografts as Predictive Preclinical Models for Anticancer Drug Activity in Humans: Better than Commonly Perceived—But They Can Be Improved (2003) (338)
- Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. (2002) (333)
- miR-30b/30d regulation of GalNAc transferases enhances invasion and immunosuppression during metastasis. (2011) (325)
- Acquired multicellular-mediated resistance to alkylating agents in cancer. (1993) (304)
- Effects of Aging and Hypoxia-Inducible Factor-1 Activity on Angiogenic Cell Mobilization and Recovery of Perfusion After Limb Ischemia (2007) (283)
- Impact of oncogenes in tumor angiogenesis: mutant K-ras up-regulation of vascular endothelial growth factor/vascular permeability factor is necessary, but not sufficient for tumorigenicity of human colorectal carcinoma cells. (1998) (278)
- Tumor and Host-Mediated Pathways of Resistance and Disease Progression in Response to Antiangiogenic Therapy (2009) (276)
- Circulating endothelial-cell kinetics and viability predict survival in breast cancer patients receiving metronomic chemotherapy. (2006) (268)
- Optimal biologic dose of metronomic chemotherapy regimens is associated with maximum antiangiogenic activity. (2005) (265)
- Oncogenes and tumor angiogenesis: differential modes of vascular endothelial growth factor up-regulation in ras-transformed epithelial cells and fibroblasts. (2000) (255)
- Possible Mechanisms of Acquired Resistance to Anti-angiogenic Drugs: Implications for the Use of Combination Therapy Approaches (2004) (253)
- Differences in therapeutic indexes of combination metronomic chemotherapy and an anti-VEGFR-2 antibody in multidrug-resistant human breast cancer xenografts. (2002) (253)
- Extent of vascularization as a prognostic indicator in thin (< 0.76 mm) malignant melanomas. (1994) (247)
- Oncogenes and angiogenesis: signaling three-dimensional tumor growth. (2000) (244)
- Consequences of angiogenesis for tumor progression, metastasis and cancer therapy. (1995) (243)
- Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression [published erratum appears in J Cell Biol 1993 Apr;121(2):following 477] (1993) (232)
- Phase I trial and pharmacokinetic study of bevacizumab in pediatric patients with refractory solid tumors: a Children's Oncology Group Study. (2008) (232)
- Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. (1996) (217)
- Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome inhibitor PS-341. (2000) (215)
- Vessel co-option in cancer (2019) (214)
- Fibroblast cell interactions with human melanoma cells affect tumor cell growth as a function of tumor progression. (1991) (214)
- A naturally occurring soluble form of vascular endothelial growth factor receptor 2 detected in mouse and human plasma. (2004) (212)
- Oncogenes and tumor angiogenesis: the HPV-16 E6 oncoprotein activates the vascular endothelial growth factor (VEGF) gene promoter in a p53 independent manner (2000) (208)
- Drug rechallenge and treatment beyond progression—implications for drug resistance (2013) (206)
- TGF-beta 1 is an autocrine-negative growth regulator of human colon carcinoma FET cells in vivo as revealed by transfection of an antisense expression vector (1992) (196)
- 'Accidental' anti-angiogenic drugs. anti-oncogene directed signal transduction inhibitors and conventional chemotherapeutic agents as examples. (2000) (195)
- Growth dominance of the metastatic cancer cell: cellular and molecular aspects. (1990) (192)
- Highly efficacious nontoxic preclinical treatment for advanced metastatic breast cancer using combination oral UFT-cyclophosphamide metronomic chemotherapy. (2006) (190)
- Continuous low-dose anti-angiogenic/ metronomic chemotherapy: from the research laboratory into the oncology clinic. (2002) (188)
- Differential expression patterns of S100a2, S100a4 and S100a6 during progression of human malignant melanoma (1997) (186)
- Interleukin 6: a fibroblast-derived growth inhibitor of human melanoma cells from early but not advanced stages of tumor progression. (1992) (181)
- Resistance of malignant trophoblast cells to both the anti-proliferative and anti-invasive effects of transforming growth factor-beta. (1994) (180)
- High-frequency Doppler ultrasound monitors the effects of antivascular therapy on tumor blood flow. (2002) (178)
- Forty-Year Journey of Angiogenesis Translational Research (2011) (178)
- Oncogenes as inducers of tumor angiogenesis (1995) (174)
- Rationale for Biomarkers and Surrogate End Points in Mechanism-Driven Oncology Drug Development (2004) (173)
- Increased Plasma Vascular Endothelial Growth Factor (VEGF) as a Surrogate Marker for Optimal Therapeutic Dosing of VEGF Receptor-2 Monoclonal Antibodies (2004) (167)
- The melanoma differentiation-associated gene mda-6, which encodes the cyclin-dependent kinase inhibitor p21, is differentially expressed during growth, differentiation and progression in human melanoma cells. (1995) (167)
- Establishing a Link between Oncogenes and Tumor Angiogenesis (1998) (163)
- Metronomic therapy with cyclophosphamide and dexamethasone for prostate carcinoma (2003) (162)
- Versican/PG‐M G3 domain promotes tumor growth and angiogenesis (2004) (161)
- Abrogation of taxol-induced G2-M arrest and apoptosis in human ovarian cancer cells grown as multicellular tumor spheroids. (1997) (159)
- Focused ultrasound delivers targeted immune cells to metastatic brain tumors. (2013) (159)
- Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia. (2006) (157)
- Vessel co‐option is common in human lung metastases and mediates resistance to anti‐angiogenic therapy in preclinical lung metastasis models (2016) (155)
- Heterogeneous vascular dependence of tumor cell populations. (2001) (151)
- Strategies for Delaying or Treating In vivo Acquired Resistance to Trastuzumab in Human Breast Cancer Xenografts (2006) (151)
- Clinical trials of antiangiogenic drugs: opportunities, problems, and assessment of initial results. (2001) (147)
- Spontaneous fusion in vivo between normal host and tumor cells: possible contribution to tumor progression and metastasis studied with a lectin-resistant mutant tumor (1983) (147)
- Massive programmed cell death in intestinal epithelial cells induced by three-dimensional growth conditions: suppression by mutant c-H-ras oncogene expression (1995) (141)
- Normoxic and hypoxic regulation of vascular endothelial growth factor (VEGF) by astrocytoma cells is mediated by Ras (1999) (138)
- Bivalent binding by intermediate affinity of nimotuzumab: A contribution to explain antibody clinical profile (2011) (136)
- Pharmacokinetics of metronomic chemotherapy: a neglected but crucial aspect (2016) (135)
- Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. (2005) (135)
- A Comparative Analysis of Low-Dose Metronomic Cyclophosphamide Reveals Absent or Low-Grade Toxicity on Tissues Highly Sensitive to the Toxic Effects of Maximum Tolerated Dose Regimens (2004) (134)
- Possible epigenetic mechanisms of tumor progression: Induction of high‐frequency heritable but phenotypically unstable changes in the tumorigenic and metastatic properties of tumor cell populations by 5‐azacytidine treatment (1984) (133)
- Cell adhesion and drug resistance in cancer (1997) (133)
- High-frequency color flow imaging of the microcirculation (2000) (132)
- The possible biological significance of Fc receptors on mammalian lymphocytes and tumor cells. (1974) (130)
- Alteration of the tumorigenic and metastatic properties of neoplastic cells is associated with the process of calcium phosphate-mediated DNA transfection. (1987) (129)
- Activated ras Prevents Downregulation of Bcl-XL Triggered by Detachment from the Extracellular Matrix (2000) (126)
- Co-option of Liver Vessels and Not Sprouting Angiogenesis Drives Acquired Sorafenib Resistance in Hepatocellular Carcinoma (2016) (126)
- Microultrasound Molecular Imaging of Vascular Endothelial Growth Factor Receptor 2 in a Mouse Model of Tumor Angiogenesis (2007) (125)
- Protein expression of the cell-cycle inhibitor p27Kip1 in malignant melanoma: inverse correlation with disease-free survival. (1998) (125)
- A role for the TGFβ-Par6 polarity pathway in breast cancer progression (2009) (123)
- Therapeutic potential of selective cyclooxygenase-2 inhibitors in the management of tumor angiogenesis. (2003) (123)
- Cyclophosphamide-methotrexate 'metronomic' chemotherapy for the palliative treatment of metastatic breast cancer. A comparative pharmacoeconomic evaluation. (2005) (121)
- Development of a preclinical model of spontaneous human melanoma central nervous system metastasis. (2008) (120)
- Antiangiogenic scheduling of lower dose cancer chemotherapy. (2001) (119)
- Enhanced immune responsiveness to a thymus‐independent antigen early after adult thymectomy: Evidence for short‐lived inhibitory thymus‐derived cells (1972) (117)
- Vascular endothelial growth factor-mediated decrease in plasma soluble vascular endothelial growth factor receptor-2 levels as a surrogate biomarker for tumor growth. (2008) (116)
- Implications of immunological heterogeneity of tumours (1979) (116)
- High-Dose Celecoxib and Metronomic “Low-dose” Cyclophosphamide Is an Effective and Safe Therapy in Patients with Relapsed and Refractory Aggressive Histology Non–Hodgkin's Lymphoma (2006) (115)
- What do oncogenic mutations have to do with angiogenesis/vascular dependence of tumors? (2002) (115)
- Clonal dominance of primary tumours by metastatic cells: genetic analysis and biological implications. (1988) (113)
- Dok‐R plays a pivotal role in angiopoietin‐1‐dependent cell migration through recruitment and activation of Pak (2001) (111)
- A model of human cancer metastasis: extensive spontaneous and artificial metastasis of a human pigmented melanoma and derived variant sublines in nude mice. (1984) (110)
- Reversal by hyaluronidase of adhesion-dependent multicellular drug resistance in mammary carcinoma cells. (1996) (110)
- Overexpression of normal and mutated forms of HRAS induces orthotopic bladder invasion in a human transitional cell carcinoma. (1990) (110)
- Antiangiogenic strategies on defense: on the possibility of blocking rebounds by the tumor vasculature after chemotherapy. (2007) (109)
- Intrinsic or acquired drug resistance and metastasis: Are they linked phenotypes? (1994) (107)
- The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells. (1995) (107)
- Genetic evidence for progressive selection and overgrowth of primary tumors by metastatic cell subpopulations. (1988) (107)
- Controlling angiogenesis in breast cancer: a systematic review of anti-angiogenic trials. (2012) (105)
- Metronomic oral topotecan prolongs survival and reduces liver metastasis in improved preclinical orthotopic and adjuvant therapy colon cancer models (2012) (105)
- Non-angiogenic tumours and their influence on cancer biology (2018) (104)
- Expression and functional activity of P-glycoprotein in cultured cerebral capillary endothelial cells. (1992) (102)
- Potent Preclinical Impact of Metronomic Low-Dose Oral Topotecan Combined with the Antiangiogenic Drug Pazopanib for the Treatment of Ovarian Cancer (2009) (101)
- Antiadhesive antibodies targeting E-cadherin sensitize multicellular tumor spheroids to chemotherapy in vitro. (2004) (101)
- von Hippel-Lindau gene-mediated growth suppression and induction of differentiation in renal cell carcinoma cells grown as multicellular tumor spheroids. (1998) (98)
- Selection of strongly immunogenic "tum-" variants from tumors at high frequency using 5-azacytidine (1984) (96)
- Acquired resistance to EGFR inhibitors: mechanisms and prevention strategies. (2004) (96)
- Development of resistance mechanisms to the growth‐inhibitory effects of transforming growth factor-β during tumor progression (1993) (95)
- Antiangiogenic and anticolorectal cancer effects of metronomic irinotecan chemotherapy alone and in combination with semaxinib (2008) (95)
- Mutagen treatment as a means for selecting immunogenic variants from otherwise poorly immunogenic malignant murine tumors. (1983) (95)
- Metronomic Low-Dose Chemotherapy Boosts CD95-Dependent Antiangiogenic Effect of the Thrombospondin Peptide ABT-510: A Complementation Antiangiogenic Strategy (2005) (94)
- Overexpression of Lerk-5/Eplg5 messenger RNA: a novel marker for increased tumorigenicity and metastatic potential in human malignant melanomas. (1998) (91)
- Molecular and cellular biomarkers for angiogenesis in clinical oncology. (2007) (91)
- A Unique Autophosphorylation Site on Tie2/Tek Mediates Dok-R Phosphotyrosine Binding Domain Binding and Function (2003) (90)
- Early treatment of HER2-amplified brain tumours with targeted nk-92 cells and focused ultrasound improves survival (2014) (89)
- Vascular endothelial growth factor isoform expression as a determinant of blood vessel patterning in human melanoma xenografts. (2002) (88)
- A cyclosporine-sensitive psoriasis-like disease produced in Tie2 transgenic mice. (2005) (88)
- TGF-beta mediated G1 arrest in a human melanoma cell line lacking p15INK4B: evidence for cooperation between p21Cip1/WAF1 and p27Kip1. (1996) (88)
- Origin and partial characterization of Fc receptor‐bearing cells found within experimental carcinomas and sarcomas (1975) (87)
- Low-dose metronomic cyclophosphamide combined with vascular disrupting therapy induces potent antitumor activity in preclinical human tumor xenograft models (2009) (86)
- Induction of a tumor with greatly increased metastatic growth potential by injection of cells from a low‐metastatic H‐2 heterozygous tumor cell line into an H‐2 incompatible parental strain (1978) (86)
- Rapid acquisition of multicellular drug resistance after a single exposure of mammary tumor cells to antitumor alkylating agents. (1994) (86)
- Pharmacology of the Novel Antiangiogenic Peptide ATN-161 (Ac-PHSCN-NH2): Observation of a U-Shaped Dose-Response Curve in Several Preclinical Models of Angiogenesis and Tumor Growth (2008) (86)
- Combined blockade of integrin-α4β1 plus cytokines SDF-1α or IL-1β potently inhibits tumor inflammation and growth. (2011) (86)
- A model of postsurgical advanced metastatic breast cancer more accurately replicates the clinical efficacy of antiangiogenic drugs. (2013) (84)
- Radiation resistance of human melanoma analysed by retroviral insertional mutagenesis reveals a possible role for dopachrome tautomerase (2004) (83)
- Downregulation of the pro-apoptotic protein Bak is required for the ras-induced transformation of intestinal epithelial cells (1998) (83)
- Disruption of cell-cell adhesion enhances antibody-dependent cellular cytotoxicity: implications for antibody-based therapeutics of cancer. (2002) (82)
- Isolation and characterization of spontaneous wheat germ agglutinin-resistant human melanoma mutants displaying remarkably different metastatic profiles in nude mice. (1988) (82)
- Anti-angiogenic treatment of breast cancer using metronomic low-dose chemotherapy. (2005) (82)
- Contribution of granulocyte colony-stimulating factor to the acute mobilization of endothelial precursor cells by vascular disrupting agents. (2009) (81)
- Imatinib mesylate (STI-571) reduces Bcr-Abl-mediated vascular endothelial growth factor secretion in chronic myelogenous leukemia. (2002) (80)
- Interleukin-6 dependent induction of the cyclin dependent kinase inhibitor p21WAF1/CIP1 is lost during progression of human malignant melanoma (1999) (80)
- Id1 Restrains p21 Expression to Control Endothelial Progenitor Cell Formation (2007) (80)
- In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. (2005) (80)
- Adhesion-dependent multicellular drug resistance. (1999) (80)
- Activated Ras prevents downregulation of Bcl-X(L) triggered by detachment from the extracellular matrix. A mechanism of Ras-induced resistance to anoikis in intestinal epithelial cells. (2000) (80)
- Metronomic Oral Topotecan with Pazopanib Is an Active Antiangiogenic Regimen in Mouse Models of Aggressive Pediatric Solid Tumor (2011) (79)
- Reversal of intrinsic and acquired forms of drug resistance by hyaluronidase treatment of solid tumors. (1998) (79)
- Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy. (2017) (78)
- Variable effects of anti-lymphocyte serum on humoral antibody formation: role of thymus dependency of antigen. (1971) (75)
- Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methotrexate, and daily prednisone as therapy for metastatic breast cancer using vascular endothelial growth factor and soluble vascular endothelial growth factor receptor levels as markers of respon (2010) (75)
- Extensive multi‐organ metastasis following orthotopic onplantation of histologically‐intact human bladder carcinoma tissue in nude mice (1991) (74)
- Contrasting effects of VEGF gene disruption in embryonic stem cell‐derived versus oncogene‐induced tumors (2003) (74)
- Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. (2011) (73)
- Multicellular resistance: a new paradigm to explain aspects of acquired drug resistance of solid tumors. (1994) (73)
- ‘Proteolytic switching’: opposite patterns of regulation of gelatinase B and its inhibitor TIMP-1 during human melanoma progression and consequences of gelatinase B overexpression (1999) (72)
- Influence of Formulation Vehicle on Metronomic Taxane Chemotherapy: Albumin-Bound versus Cremophor EL–Based Paclitaxel (2006) (71)
- Multicellular gastric cancer spheroids recapitulate growth pattern and differentiation phenotype of human gastric carcinomas. (2001) (70)
- Enhanced expression of class I major histocompatibility complex gene (Dk) products on immunogenic variants of a spontaneous murine carcinoma. (1985) (70)
- Low-dose metronomic daily cyclophosphamide and weekly tirapazamine: a well-tolerated combination regimen with enhanced efficacy that exploits tumor hypoxia. (2006) (70)
- Repression of autocrine transforming growth factor beta 1 and beta 2 in quiescent CBS colon carcinoma cells leads to progression of tumorigenic properties. (1993) (70)
- Enhanced tumorigenicity, melanogenesis, and metastases of a human malignant melanoma after subdermal implantation in nude mice. (1989) (69)
- A paradigm for therapy-induced microenvironmental changes in solid tumors leading to drug resistance. (2002) (69)
- Reappraising antiangiogenic therapy for breast cancer. (2011) (68)
- Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy. (2010) (68)
- A pharmacokinetic and pharmacodynamic study on metronomic irinotecan in metastatic colorectal cancer patients (2008) (68)
- Modulation by interferons of HLA antigen, high-molecular-weight melanoma associated antigen, and intercellular adhesion molecule 1 expression by cultured melanoma cells with different metastatic potential. (1989) (67)
- Cytokines, growth factors and the loss of negative growth controls in the progression of human cutaneous malignant melanoma. (1994) (67)
- High-frequency 3-D color-flow imaging of the microcirculation. (2003) (67)
- What is the Optimal Rodent Model for Anti-tumor Drug Testing? (1998) (67)
- Ras regulation of vascular endothelial growth factor and angiogenesis. (2001) (65)
- PLEKHA5 as a Biomarker and Potential Mediator of Melanoma Brain Metastasis (2014) (65)
- Therapeutic implications of intrinsic or induced angiogenic growth factor redundancy in tumors revealed. (2005) (65)
- Apparent reversion of stable in vitro genetic markers detected in tumour cells from spontaneous metastases (1981) (64)
- Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers (2012) (64)
- Effects of Sorafenib Dose on Acquired Reversible Resistance and Toxicity in Hepatocellular Carcinoma. (2015) (63)
- Anti-tumor effect of CT-322 as an Adnectin inhibitor of vascular endothelial growth factor receptor-2 (2010) (63)
- Translational Impact of Nanoparticle–Drug Conjugate CRLX101 with or without Bevacizumab in Advanced Ovarian Cancer (2014) (63)
- Induction of anoikis and suppression of human ovarian tumor growth in vivo by down-regulation of Bcl-X(L). (2001) (62)
- Characterization of a deficiency in fucose metabolism in lectin-resistant variants of a murine tumor showing altered tumorigenic and metastatic capacities in vivo. (1981) (62)
- An assessment of intratumor phagocytic and surface marker-bearing cells in a series of autochthonous and early passaged chemically induced murine sarcomas. (1976) (62)
- Induction and reversal of cell adhesion-dependent multicellular drug resistance in solid breast tumors. (1996) (61)
- Antitumor effects of combining metronomic chemotherapy with the antivascular action of ultrasound stimulated microbubbles (2013) (61)
- Highly pigmented human melanoma variant which metastasizes widely in nude mice, including to skin and brain. (1988) (60)
- Vascular endothelial growth factor levels in immunodepleted plasma of cancer patients as a possible pharmacodynamic marker for bevacizumab activity. (2007) (60)
- Tumor cell surface beta 1-4-linked galactose binds to lectin(s) on microvascular endothelial cells and contributes to organ colonization (1990) (60)
- Cyclin kinase inhibitor p21WAF1/CIP1 in malignant melanoma: reduced expression in metastatic lesions. (1996) (60)
- Tyrosinase-related protein 2 as a mediator of melanoma specific resistance to cis-diamminedichloroplatinum(II): therapeutic implications (2000) (59)
- Roles for endothelin receptor B and BCL2A1 in spontaneous CNS metastasis of melanoma. (2012) (59)
- Transforming growth factor beta 1 (TGF beta 1) is an autocrine positive regulator of colon carcinoma U9 cells in vivo as shown by transfection of a TGF beta 1 antisense expression plasmid. (1995) (58)
- Possible involvement of Ca2+ mobilization and protein kinase C activation in the induction of spontaneous metastasis by mouse mammary adenocarcinoma cells. (1989) (58)
- ras Oncogene Triggers Up-regulation of cIAP2 and XIAP in Intestinal Epithelial Cells (2005) (58)
- G-CSF supplementation with chemotherapy can promote revascularization and subsequent tumor regrowth: prevention by a CXCR4 antagonist. (2011) (58)
- Endothelial progenitor cells are cellular hubs essential for neoangiogenesis of certain aggressive adenocarcinomas and metastatic transition but not adenomas (2008) (58)
- Biomarkers, Surrogate End Points, and the Acceleration of Drug Development for Cancer Prevention and Treatment (2004) (57)
- Raising the bar for cancer therapy models (2010) (56)
- Gene Expression Analysis of Tumor Spheroids Reveals a Role for Suppressed DNA Mismatch Repair in Multicellular Resistance to Alkylating Agents (2004) (56)
- bFGF and tumor angiogenesis — Back in the limelight? (1997) (56)
- Progressive loss of sensitivity to endothelium‐derived growth inhibitors expressed by human melanoma cells during disease progression (1994) (55)
- Endogenous interleukin 6 can function as an in vivo growth- stimulatory factor for advanced-stage human melanoma cells. (1996) (55)
- Selection of metastatic variants with identifiable karyotypic changes from a nonmetastatic murine tumor after treatment with 2'-deoxy-5-azacytidine or hydroxyurea: implications for the mechanisms of tumor progression. (1987) (55)
- Increased resistance to oncostatin M-induced growth inhibition of human melanoma cell lines derived from advanced-stage lesions. (1993) (53)
- Treating cancer by inhibiting angiogenesis: new hopes and potential pitfall (1996) (52)
- RB2/p130 gene-enhanced expression down-regulates vascular endothelial growth factor expression and inhibits angiogenesis in vivo. (2001) (51)
- CLASSIFICATION OF THYMUS-DERIVED AND MARROW-DERIVED LYMPHOCYTES BY DEMONSTRATION OF THEIR ANTIGEN-BINDING CHARACTERISTICS (1972) (49)
- Phosphorylated epidermal growth factor receptor on tumor-associated endothelial cells is a primary target for therapy with tyrosine kinase inhibitors. (2008) (49)
- Collateral expression of proangiogenic and tumorigenic properties in intestinal epithelial cell variants selected for resistance to anoikis. (1999) (49)
- Ha-ras induction of the invasive phenotype results in up-regulation of epidermal growth factor receptors and altered responsiveness to epidermal growth factor in human papillary transitional cell carcinoma cells. (1991) (49)
- Impact of metronomic UFT/cyclophosphamide chemotherapy and antiangiogenic drug assessed in a new preclinical model of locally advanced orthotopic hepatocellular carcinoma. (2010) (49)
- The potential clinical promise of 'multimodality' metronomic chemotherapy revealed by preclinical studies of metastatic disease. (2017) (49)
- Cellular and molecular surrogate markers to monitor targeted and non-targeted antiangiogenic drug activity and determine optimal biologic dose. (2005) (49)
- Improving conventional or low dose metronomic chemotherapy with targeted antiangiogenic drugs. (2007) (48)
- The multiple personality disorder phenotype(s) of circulating endothelial cells in cancer. (2009) (48)
- Metastatic potential of SP1 mouse mammary adenocarcinoma cells is differentially induced by activated and normal forms of c-H-ras. (1987) (47)
- Preclinical Efficacy of Bevacizumab with CRLX101, an Investigational Nanoparticle-Drug Conjugate, in Treatment of Metastatic Triple-Negative Breast Cancer. (2016) (47)
- A Decade of Experience in Developing Preclinical Models of Advanced- or Early-Stage Spontaneous Metastasis to Study Antiangiogenic Drugs, Metronomic Chemotherapy, and the Tumor Microenvironment (2015) (47)
- Multiple features of advanced melanoma recapitulated in tumorigenic variants of early stage (radial growth phase) human melanoma cell lines: evidence for a dominant phenotype. (1996) (47)
- Postsurgical adjuvant or metastatic renal cell carcinoma therapy models reveal potent antitumor activity of metronomic oral topotecan with pazopanib (2015) (46)
- Pharmacodynamic and pharmacokinetic study of chronic low-dose metronomic cyclophosphamide therapy in mice (2007) (46)
- On a possible epigenetic mechanism(s) of tumor cell heterogeneity (2004) (46)
- Evidence Implicating Immunological Host Effects in the Efficacy of Metronomic Low-Dose Chemotherapy. (2016) (46)
- Potent efficacy of metronomic topotecan and pazopanib combination therapy in preclinical models of primary or late stage metastatic triple-negative breast cancer (2015) (46)
- On the development of models in mice of advanced visceral metastatic disease for anti-cancer drug testing (2007) (45)
- Genetic tagging of tumor cells with retrovirus vectors: clonal analysis of tumor growth and metastasis in vivo (1988) (45)
- Mechanisms of cellular invasiveness: a comparison of amnion invasion in vitro and metastatic behavior in vivo. (1989) (45)
- Cancer: Chemotherapy counteracted (2010) (45)
- Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis. (2013) (44)
- Comparative Impact of Trastuzumab and Cyclophosphamide on HER-2–Positive Human Breast Cancer Xenografts (2009) (44)
- Tumor-associated fibroblasts as "Trojan Horse" mediators of resistance to anti-VEGF therapy. (2009) (44)
- Preclinical approaches to study the biology and treatment of brain metastases. (2011) (44)
- Identification of somatostatin receptors in human small cell lung carcinoma (1990) (43)
- Carcinogenicity of tumor cell populations: origin of a putative H-2 isoantigenic loss variant tumor. (1980) (43)
- Interleukin 12: newest member of the antiangiogenesis club. (1995) (42)
- Low-Dose Metronomic Oral Dosing of a Prodrug of Gemcitabine (LY2334737) Causes Antitumor Effects in the Absence of Inhibition of Systemic Vasculogenesis (2011) (42)
- Expression of multi-cytokine resistance and multi-growth factor independence in advanced stage metastatic cancer. Malignant melanoma as a paradigm. (1992) (41)
- Neoadjuvant antiangiogenic therapy reveals contrasts in primary and metastatic tumor efficacy (2014) (40)
- Issues regarding improving the impact of antiangiogenic drugs for the treatment of breast cancer. (2009) (40)
- Rapid adsorption of a foetal calf serum component by mammalian cells in culture. A potential source of artifacts in studies of antisera to cell-specific antigens. (1976) (39)
- Variant sublines of early-stage human melanomas selected for tumorigenicity in nude mice express a multicytokine-resistant phenotype. (1994) (39)
- Efficacy of Cotargeting Angiopoietin-2 and the VEGF Pathway in the Adjuvant Postsurgical Setting for Early Breast, Colorectal, and Renal Cancers. (2016) (39)
- Detecting vascular changes in tumour xenografts using micro-ultrasound and micro-ct following treatment with VEGFR-2 blocking antibodies. (2007) (38)
- Differential Post-Surgical Metastasis and Survival in SCID, NOD-SCID and NOD-SCID-IL-2Rγnull Mice with Parental and Subline Variants of Human Breast Cancer: Implications for Host Defense Mechanisms Regulating Metastasis (2013) (38)
- Dose-Dependent Increases in Circulating TGF-α and Other EGFR Ligands Act As Pharmacodynamic Markers for Optimal Biological Dosing of Cetuximab and Are Tumor Independent (2009) (38)
- Strategies for Improving the Clinical Benefit of Antiangiogenic Drug Based Therapies for Breast Cancer (2012) (38)
- High frequency color flow imaging of the microcirculation (1998) (38)
- Metronomic chemotherapy: possible clinical application in advanced hepatocellular carcinoma. (2013) (37)
- Down-regulation of DNA mismatch repair proteins in human and murine tumor spheroids: implications for multicellular resistance to alkylating agents (2005) (37)
- Anti‐vascular endothelial growth factor receptor‐2 (Flk‐1/KDR) antibody suppresses contact hypersensitivity (2004) (37)
- Membrane-associated alterations detected in poorly tumorigenic lectin-resistant variant sublines of a highly malignant and metastatic murine tumor. (1981) (37)
- FACILITATION OF TUMOUR PROGRESSION BY CANCER THERAPY (1982) (36)
- Reduced levels of DNA 5-methylcytosine in metastatic variants of the human melanoma cell line MeWo. (1987) (36)
- Metronomic chemotherapy: principles and lessons learned from applications in the treatment of metastatic prostate cancer. (2010) (36)
- Vasohibin: the feedback on a new inhibitor of angiogenesis. (2004) (36)
- Cure of human melanoma lung metastases in nude mice with chronic indomethacin therapy combined with multiple rounds of IL-2: characteristics of killer cells generated in situ. (1990) (35)
- The splenic microenvironment is a source of proangiogenesis/inflammatory mediators accelerating the expansion of murine erythroleukemic cells. (2005) (34)
- Constitutive production of 92-kDa gelatinase B can be suppressed by alterations in cell shape. (1995) (34)
- Importance of orthotopic transplantation procedures in assessing the effects of transfected genes on human tumor growth and metastasis (1991) (34)
- Dominance of metastatically competent cells in primary murine breast neoplasms is necessary for distant metastatic spread (1991) (34)
- Dok-R Binds c-Abl and Regulates Abl Kinase Activity and Mediates Cytoskeletal Reorganization* (2003) (33)
- Abrogation of the in vitro generation of the cytotoxic T‐cell response to a murine tumor: The role of suppressor cells (1982) (33)
- Differences in vasculature between pilocytic and anaplastic astrocytomas of childhood. (2003) (33)
- Five Years of Clinical Experience with Metronomic Chemotherapy: Achievements and Perspectives (2007) (32)
- Expression of leukemia inhibitory factor and interleukin-11 by human melanoma cell lines: LIF, IL-6, and IL-11 are not coregulated. (1995) (32)
- Molecular and Physiologic Mechanisms of Drug Resistance in Cancer: An Overview (2004) (32)
- The dormant in vivo phenotype of early stage primary human melanoma: termination by overexpression of vascular endothelial growth factor (2004) (31)
- Genotypic and phenotypic evolution of a murine tumor during its progression in vivo toward metastasis. (1983) (31)
- Antiangiogenic drugs and current strategies for the treatment of lung cancer. (2004) (31)
- Lymphocyte: Erythrocyte (L.E.) rosettes as indicators of the heterogeneity of lymphocytes in a variety of mammalian species (1975) (31)
- Long-term progression and therapeutic response of visceral metastatic disease non-invasively monitored in mouse urine using β-human choriogonadotropin secreting tumor cell lines (2008) (31)
- Lessons from the Fourth Metronomic and Anti-angiogenic Therapy Meeting, 24–25 June 2014, Milan (2014) (30)
- Effective Treatment of Advanced Human Melanoma Metastasis in Immunodeficient Mice Using Combination Metronomic Chemotherapy Regimens (2009) (30)
- Enhanced natural-killer cell and erythropoietic activities in VEGF-A-overexpressing mice delay F-MuLV-induced erythroleukemia. (2007) (30)
- TYRP2-mediated resistance to cis-diamminedichloroplatinum (II) in human melanoma cells is independent of tyrosinase and TYRP1 expression and melanin content (2000) (29)
- Antiproliferative and proapoptotic activity of sunitinib on endothelial and anaplastic thyroid cancer cells via inhibition of Akt and ERK1/2 phosphorylation and by down-regulation of cyclin-D1. (2013) (29)
- Retroviral insertional mutagenesis as a strategy for the identification of genes associated with cis-diamminedichloroplatinum(II) resistance. (1995) (29)
- Immunologic studies of membrane mutants of a highly metastatic murine tumor. (1979) (29)
- Anti-VEGF therapy reduces intestinal inflammation in Endoglin heterozygous mice subjected to experimental colitis (2014) (29)
- Vasculotide reduces endothelial permeability and tumor cell extravasation in the absence of binding to or agonistic activation of Tie2 (2015) (28)
- Hypomethylation and reactivation of the asparagine synthetase gene induced by L-asparaginase and ethyl methanesulfonate. (1991) (28)
- Alterations in sensitivity to nonspecific cell-mediated lysis associated with tumor progression: characterization of activated macrophage- and natural killer cell-resistant tumor variants. (1984) (28)
- Lineage-specific Mechanism of Drug and Radiation Resistance in Melanoma Mediated by Tyrosinase-related Protein 2 (2004) (27)
- Reduction of TGF‐beta activity abrogates growth promoting tumor cell‐cell interactions in vivo (1991) (27)
- Immunoselection in vitro of a non‐metastatic variant from a highly metastatic tumor (1981) (27)
- 5-azacytidine induction of thymidine kinase in a spontaneously enzyme-deficient murine tumor line. (1984) (27)
- Demonstration of a correlation between tumor cell H-2 antigen content, immunogenicity, and tumorigenicity using lectin-resistant tumor variants. (1981) (26)
- Potential Proinvasive or Metastatic Effects of Preclinical Antiangiogenic Therapy Are Prevented by Concurrent Chemotherapy (2015) (26)
- Peering into the aftermath: The inhospitable host? (2010) (26)
- Microparticles from tumors exposed to radiation promote immune evasion in part by PD-L1 (2019) (26)
- Fc receptor‐bearing cells as a reliable marker for quantitation of host lymphoreticular infiltration of progressively growing solid tumors (1976) (26)
- FURTHER STUDIES OF ANTIGENIC COMPETITION III. A MODEL TO ACCOUNT FOR THE PHENOMENON BASED ON A DEFICIENCY OF CELL-TO-CELL INTERACTION IN IMMUNE LYMPHOID CELL POPULATIONS (1971) (25)
- Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer (2019) (25)
- Preliminary Investigation of Focused Ultrasound-Facilitated Drug Delivery for the Treatment of Leptomeningeal Metastases (2018) (25)
- Antiangiogenic Therapy in Advanced Non–small‐cell Lung Cancer: A Meta‐analysis of Phase III Randomized Trials (2017) (24)
- Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease (2018) (24)
- Preclinical analysis of resistance and cross-resistance to low-dose metronomic chemotherapy (2013) (23)
- Metastatic properties of distinct phenotypic classes of lectin-resistant mutants isolated from murine MDAY-D2 cell line (1984) (23)
- Tumor progression in metastasis: an experimental approach using lectin resistant tumor variants (2004) (23)
- Oncogenes and Tumor Angiogenesis (2004) (23)
- Metronomic S-1 chemotherapy and vandetanib: an efficacious and nontoxic treatment for hepatocellular carcinoma. (2011) (23)
- Gastrointestinal cancer: Rationale for metronomic chemotherapy in phase III trials (2015) (23)
- Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer (2014) (22)
- Lenalidomide and metronomic melphalan for CMML and higher risk MDS: a phase 2 clinical study with biomarkers of angiogenesis. (2014) (21)
- Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatment (2013) (21)
- Failure of expression of class I major histocompatibility antigens to alter tumor immunogenicity of a spontaneous murine carcinoma. (1989) (21)
- Immune-mediated arrest and reversal of established visceral metastases in athymic mice. (1979) (21)
- Development of Patient Derived Xenograft Models of Overt Spontaneous Breast Cancer Metastasis: A Cautionary Note (2016) (21)
- Analysis of established human carcinoma cell lines for lymphoreticular‐associated membrane receptors (1977) (20)
- Generation of highly metastatic tumors in DBA/2 mice. Oncogenicity of a strain tumor cells. (1981) (20)
- Selective natural killer resistance in a clone of YAC lymphoma cells. (1981) (20)
- Functional dissociation of anoikis-like cell death and activity of stress activated protein kinase. (1999) (19)
- Significance of tumor-host interactions in cancer growth and metastases (1995) (19)
- Cytogenetic heterogeneity of genetically marked and metastatically competent "dominant" tumor cell clones. (1991) (19)
- An examination of tumor antigen loss in spontaneous metastases. (1981) (19)
- Autocrine and paracrine regulation of tissue inhibitor of metalloproteinases, transin, and urokinase gene expression in metastatic and nonmetastatic mammary carcinoma cells. (1991) (19)
- Differential induction by immune interferon of the gene products of the HLA-D region on the melanoma cell line MeWo and its metastatic variant MeM 50-10. (1988) (18)
- Reanalysis of Cancer Drugs (2004) (18)
- Implications of vessel co-option in sorafenib-resistant hepatocellular carcinoma (2016) (18)
- Cloning and overexpression of TGF-beta 1 cDNA in a mammary adenocarcinoma: in vitro and in vivo effects. (1991) (18)
- Careful decoy receptor titering is required to inhibit tumor angiogenesis while avoiding adversely altering VEGF bioavailability. (2005) (18)
- Single-step selection of unique human melanoma variants displaying unusually aggressive metastatic behavior in nude athymic mice. (1984) (18)
- Impact of multicellular resistance on the survival of solid tumors, including micrometastases. (1994) (17)
- Liver surgery induces an immediate mobilization of progenitor cells in liver cancer patients: A potential role for G-CSF (2010) (17)
- A Comparative Analysis of Cell Surface Markers on Murine NK Cells and CTL Target‐Effector Conjugates (1982) (17)
- Adult and pre-adult thymectomy of mice: contrasting effects on immune responsiveness, and on numbers of mitogen-responsive and Thy-1+ lymphocytes. (1979) (17)
- Impact of Chemical-Induced Mutational Load Increase on Immune Checkpoint Therapy in Poorly Responsive Murine Tumors (2018) (17)
- On the origin and nature of elevated levels of circulating endothelial cells after treatment with a vascular disrupting agent. (2006) (16)
- Development and characterization of a clinically relevant mouse model of melanoma brain metastasis (2013) (16)
- Analysis and significance of the malignant 'eclipse' during the progression of primary cutaneous human melanomas. (1996) (16)
- Constitutive expression and secretion of proteases in non‐metastatic SP1 mammary carcinoma cells and its metastatic sublines (1991) (15)
- Relevance of spontaneous in vivo tumor-host cell fusion to tumor progression and metastasis evaluated using a series of lectin-resistant mutant tumor sublines. (1983) (15)
- Aflibercept and Ang1 supplementation improve neoadjuvant or adjuvant chemotherapy in a preclinical model of resectable breast cancer (2016) (15)
- A Dynamic De-Escalating Dosing Strategy to Determine the Optimal Biological Dose for Antiangiogenic Drugs (2005) (15)
- Next generation metronomic chemotherapy—report from the Fifth Biennial International Metronomic and Anti-angiogenic Therapy Meeting, 6–8 May 2016, Mumbai (2016) (15)
- Anti-vascular endothelial growth factor receptor-2 antibody accelerates renal disease in the NZB/W F1 murine systemic lupus erythematosus model. (2005) (15)
- Resistance of mitotic B lymphocytes to cytotoxic effects of anti-Ig serum (1974) (14)
- Increased sensitivity of rosetting assay for Fc receptors obtained by using non-hemagglutinating monoclonal antibodies. (1980) (14)
- Temsirolimus Maintenance Therapy After Docetaxel Induction in Castration-Resistant Prostate Cancer. (2015) (14)
- Towards an understanding of the molecular basis of the metastatic phenotype. (1989) (14)
- Basement membrane invasion by first trimester human trophoblast: requirement for branched complex-type Asn-linked oligosaccharides (1990) (13)
- Induction of thymidine kinase activity in a spontaneously enzyme-deficient murine tumor cell line by exposure in vivo to the DNA-hypomethylating agent 5-aza-2'-deoxycytidine: implications for mechanisms of tumor progression. (1985) (13)
- New insights into the evolutionary growth of tumors revealed by Southern gel analysis of tumors genetically tagged with plasmid or proviral DNA insertions. (1989) (13)
- The Role of Angiogenesis in Tumor Progression and Metastasis (1993) (13)
- Circulating endothelial progenitor cells. (2005) (13)
- Adoptive immune therapy in mice bearing poorly immunogenic metastases, using T lymphocytes stimulated in vitro against highly immunogenic mutant sublines (1984) (12)
- NGR-TNF, a novel vascular-targeting agent, does not induce cytokine recruitment of proangiogenic bone marrow-derived cells (2013) (12)
- Metronomic chemotherapy offsets HIFα induction upon maximum‐tolerated dose in metastatic cancers (2020) (12)
- New targets, drugs, and approaches for the treatment of cancer: An overview (1998) (12)
- Periodate-oxidized adenosine induction of murine thymidine kinase: role of DNA methylation in the generation of tumor cell heterogeneity. (1986) (11)
- Rosette formation by a mouse fibroblast cell line (1974) (11)
- Heritable high frequency modulation of antigen expression in neoplastic cells exposed to 5-aza-2'-deoxycytidine or hydroxyurea: analysis and implications. (1988) (11)
- Resistance of activated macrophages to H–2 antibody-mediated cytotoxicity and Fc rosette inhibition (1976) (11)
- Characterization of a metastasis‐deficient lectin‐resistant human melanoma mutant (1989) (11)
- Detection of Fc receptors. (1983) (11)
- Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer (2020) (11)
- Monoclonal Antibodies in Cancer Therapy: An Overview (1999) (10)
- Ang2 inhibitors and Tie2 activators: potential therapeutics in perioperative treatment of early stage cancer (2021) (10)
- S7 Combination cyclophosphamide — UFT metronomic low-dose chemotherapy for the treatment of metastatic breast cancer: A preclinical analysis (2005) (10)
- Ultrastructural and serological studies on the resistance of activated B cells to the cytotoxic effects of anti-immunoglobulin serum. Patch and cap formation of surface immunoglobulin on mitotic B lymphocytes. (1975) (10)
- Antiangiogenic therapy: impact on invasion, disease progression, and metastasis (2011) (10)
- Interleukin 6 in progression of human solid tumors : transitional changes in the regulation of cell growth, apoptosis and angiogenesis (1997) (10)
- Therapy-activated stromal cells can dictate tumor fate (2016) (10)
- Further studies of competition of antigens. I. Variation in immunosuppression induced by alterations of dosage, route of injection, nature of antigen, and immunological status of host. (1971) (10)
- Ia antigens and Fc receptors (1975) (10)
- Potentiation of growth suppression and modulation of the antigenic phenotype in human melanoma cells by the combination of recombinant human fibroblast and immune interferons (2005) (10)
- Repression of Autocrine Transforming Growth Factor and / 32 in Quiescent CBS Colon Carcinoma Cells Leads to Progression of Tumorigenic Properties (2005) (10)
- Transglutaminase stabilizes melanoma adhesion under laminar flow (1991) (10)
- New hypothesis on antigenic competition based on cell interactions in the immune response. (1971) (9)
- Surface Antigen Changes Accompanying Lymphocyte Activation (1977) (9)
- Assessment of mitotic thymus-derived lymphocytes by their sensitivity to the cytotoxic effects of anti-theta serum. (1974) (9)
- Immunostimulatory and anti-tumor metronomic cyclophosphamide regimens assessed in primary orthotopic and metastatic murine breast cancer (2020) (9)
- Genetic and epigenetic aspects of tumor progression and tumor heterogeneity. (1985) (9)
- Genetic and Epigenetic Regulation of the Metastatic Phenotype: A Basis for Resolving the Controversy Regarding its Selective or Random Nature and Variable Phenotypic Stability (1986) (9)
- Tumors resurrect an embryonic vascular program to escape immunity (2022) (8)
- Induction of a malignant lymphoreticular cell line which displays spontaneous killer‐cell activity (1981) (8)
- A CD276 Antibody Guided Missile with One Warhead and Two Targets: The Tumor and Its Vasculature. (2017) (8)
- Growth advantage (“clonal dominance”) of metastatically competent tumor cell variants expressed under selective two- or three-dimensional tissue culture conditions (1993) (8)
- Suppressive impact of metronomic chemotherapy using UFT and/or cyclophosphamide on mediators of breast cancer dissemination and invasion (2019) (7)
- Growth factors as mediators of malignant tumor progression (1993) (7)
- Clonal changes in tumours during growth and progression evaluated by southern gel analysis of random integrations of foreign DNA. (1988) (7)
- Spatiotemporal assessment of spontaneous metastasis formation using multimodal in vivo imaging in HER2+ and triple negative metastatic breast cancer xenograft models in mice (2018) (7)
- Cyclin kinase inhibitor p21(WAF1/CIP1) in malignant melanoma (1996) (7)
- Microbubble ultrasound (DCE-US) compared to DCE-MRI and DCE-CT for the assessment of vascular response to sunitinib in renal cell carcinoma (RCC). (2011) (7)
- Is there a role for anti-adhesives as chemosensitizers in the treatment of solid tumours by chemotherapy ? : Metastases (1994) (7)
- Plasma vascular endothelial growth factor as a predictive biomarker: Door closed? (2017) (7)
- Phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC). (2011) (7)
- Compendium of immunology. 2nd edition, By L. M. Schwartz. New York: Van Nostrand Reinhold. 515 pp. $32.50 (1980) (7)
- Basic fibroblast growth factor and the complexity of tumour angiogenesis. (1998) (7)
- Herpes virus induction of Fc receptors (1976) (6)
- Palliation of relapsed aggressive histology NHL with high-dose celecoxib and 'metronomic' low-dose cyclophosphamide. (2004) (6)
- Metronomic chemotherapy for triple negative breast cancer? (2016) (6)
- Immunology of metastasis (1983) (6)
- Effects of Aging and Hypoxia-Inducible Factor-1 Activity on Angiogenic Cell Mobilization and Recovery of Perfusion Following Limb Ischemia (2007) (5)
- Selective anti-endothelial effects of protracted low-dose BAL-9504, a novel geranylgeranyl-transferase inhibitor. (2003) (5)
- Development and Evolution of the Concept of Metronomic Chemotherapy: A Personal Perspective (2014) (5)
- TGF-β gene expression depends on tissue architecture (1993) (5)
- An eosinophil immune response characterizes the inflammatory skin disease observed in Tie‐2 transgenic mice (2008) (5)
- Are there Fc receptors on non-lymphoreticular tumor cells? (1980) (5)
- Enumeration of polyclonal mitogen-responsive cells in different lymphoid tissues of the mouse. (1976) (5)
- Preclinical impact of high dose intermittent antiangiogenic tyrosine kinase inhibitor pazopanib in intrinsically resistant tumor models (2018) (5)
- Tumor-Independent Host Secretomes Induced By Angiogenesis and Immune-Checkpoint Inhibitors (2018) (5)
- A new Tie1 targeted antibody blocks tumor cell extravasation and metastasis (2020) (5)
- Characterization of In vitro immunoselected variants from a highly metastatic murine tumor for alterations in malignant behavior in vivo (1984) (5)
- Tumor Cell Subpopulation Interactions Mediated by Transforming Growth Factor β May Contribute to Clonal Dominance of Metastatically Competent Cells in Primary Tumors (1990) (5)
- Adjuvant metronomic chemotherapy for locoregionally advanced nasopharyngeal carcinoma (2021) (4)
- High Dose Celecoxib and Metronomic ‘Low-Dose’ Cyclophosphamide Is Effective Therapy in Patients with Relapsed and Refractory Aggressive Histology NHL. (2004) (4)
- Lack of influence of c-Ha-ras expression on the drug sensitivity of human bladder cancer histocultured in three-dimensions. (1993) (4)
- TGF-beta gene expression depends on tissue architecture. (1993) (4)
- Anti-angiogenesis in cancer; met and unmet goals - an interview with Robert Kerbel by Francesco Bertolini. (2011) (4)
- EA rosettes using IgG monoclonal antibody-coated erythrocytes: degree of rosette formation correlates with the amount of antibody on the erythrocytes. (1981) (4)
- Analysis of growth, selection, and metastasis of tumor cell populations in vivo using random insertions of foreign DNA as genetic tags. (1988) (4)
- Variable impact of three different antiangiogenic drugs alone or in combination with chemotherapy on multiple bone marrow-derived cell populations involved in angiogenesis and immunity (2019) (3)
- Effect of the timing of sunitinib administration on the predictive value of biomarkers in renal cell cancer (mRCC). (2015) (3)
- Tumor specific antigens induced by mutagens and DNA hypomethylating agents: implications for the immunobiology of neoplasia (1986) (3)
- Metronomic ABI-007 therapy: antiangiogenic and antitumor activity of a nanoparticle albumin-bound paclitaxel (2005) (3)
- Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents (2019) (3)
- Phase I-II study of DalCM-P [daily dalteparin (Dal), cyclophosphamide (C) and prednisone (P) and bi-weekly methotrexate (M)] as therapy for metastatic breast cancer (MBC) (2005) (3)
- On the possible contribution of DNA hypomethylation to the induction of high frequency and heritable drug-induced alterations in the malignant phenotype. (1986) (3)
- On coalescent angiogenesis and the remarkable flexibility of blood vessels (2022) (3)
- Clinical, pharmacokinetic and pharmacodynamic evaluations of metronomic UFT and cyclophosphamide plus celecoxib in patients with advanced refractory gastrointestinal cancers (2012) (3)
- Fc receptors and Ia antigens: a postscript (1975) (2)
- Tumor Cells Genetically Tagged with Transferred DNA Markers Reveal Evidence for Clonal Dominance of Primary Tumors by Metastatic Subpopulations (1989) (2)
- O-1-10 Astrocytomas express high levels of vascular endothelial growth factor (VEGF) which are reduced through RAS pathway inhibition (1997) (2)
- High frequency 3D flow imaging of the microcirculation (1999) (2)
- Abstract PR09: Synergistic activity of CRLX101, a nanopharmaceutical in Phase II clinical trials, with antiangiogenic therapies mediated through HIF-1alpha inhibition: A translational research program. (2013) (2)
- Tumor Angiogenesis and the Cancer Stem Cell Model (2008) (2)
- CRITICAL ISSU-ES IN TUMOR MICROCIRCULATION, ANGIOGENESIS AND METASTASIS: BIOLOGICAL SIGNIFICANCE AND CLINICAL RELEVANCE (1993) (2)
- Metronomic Low-Dose Antiangiogenic Chemotherapy in Mice and Man (2008) (2)
- Is the immunotherapy of metastasis feasible? (1986) (2)
- Recent Advances in Angiogenesis and Antiangiogenesis (2018) (2)
- S14 Modulation of angiogenesis: Clinical impact (in breast cancer) (2009) (2)
- Development of preclinical models of human BT474 and MDA-MB-361 breast cancer that endogenously overexpress HER2 and that respond to trastuzumab. (2012) (2)
- Combining Antiangiogenic Drugs with Vascular Disrupting Agents Rationale and Mechanisms of Action (2010) (2)
- A simple and convenient method for producing anti-activated lymphocyte alloantisera which does not require prior absorption. (1978) (2)
- Advances in Brief RB 2 / p 130 Gene-enhanced Expression Down-Regulates Vascular Endothelial Growth Factor Expression and Inhibits Angiogenesis in Vivo 1 (2001) (2)
- Surface receptors on lymphoreticular cells: sensory devices for host recognition of foreign antigens and neoplasia. (1980) (1)
- Some Guidelines to Building a Successful Laboratory and Career in Cancer Research (2003) (1)
- Host cell analysis of a rapidly metastasizing mouse tumor and derived low-metastatic variant lines. (1980) (1)
- Impact of circulating endothelial progenitor cells on the growth of viable tumor rim after treatment with a vascular disrupting agent. (2006) (1)
- Commentaries on tumor angiogenesis: an introduction (1996) (1)
- Transition in Responsiveness to Multiple Inhibitory Growth Factors: Possible Contribution to Tumor Progression and Metastasis (1992) (1)
- Antiangiogenic drugs as broadly effective chemosensitizing agents (2006) (1)
- Preliminary results of a phase II study of continuous low dose metronomic (LDM) cyclophosphamide (CTX) and celecoxib (CEL) for asymptomatic hormone refractory prostate cancer (HRPC) with assessment of anti-angiogenic biomarkers (2007) (1)
- Monitoring antivascular therapy with high frequency ultrasound flow imaging (2002) (1)
- Personalized use of metronomic cyclophosphamide for DNA repair deficient castration-resistant prostate cancer: A phase II trial. (2019) (1)
- Vascular Endothelial Growth Factor Isoform Expression as a Determinant of Blood Vessel Patterning in Human Melanoma Xenografts 1 (2002) (1)
- Taxanes Induce a Rapid Mobilization of Different Populations of Circulating Endothelial Progenitors by SDF-1 Modulation in Cancer Patients. (2008) (1)
- Angiogenesis Inhibitors as Enabling Agents for the Chemotherapeutic Treatment of Metastatic Disease (2008) (1)
- Abstract 1946: Identification of miRNAs that contribute to melanoma brain metastasis (2010) (1)
- Advances in Brief Maximum Tolerable Dose and Low-Dose Metronomic Chemotherapy Have Opposite Effects on the Mobilization and Viability of Circulating Endothelial Progenitor Cells 1 (2003) (1)
- Impaired Autophagy Mediates Resistance to Low-Dose Metronomic Cyclophosphamide Chemotherapy (2014) (1)
- Modeling Therapy of Late or Early‐Stage Metastatic Disease in Mice (2017) (1)
- A marker for activated macrophages based on resistance of fc rosette formation to the inhibiting effects of anti-h2 serum. Abstr. (1976) (1)
- Microbubble ultrasound compared to dynamic contrast MRI and CT for the assessment of vascular response to sunitinib in renal cell carcinoma. (2010) (1)
- Anomalous reactivity of anti‐T cell sera on spleen cells from T‐cell‐deprived mice and on mitogen‐stimulated nude mice spleen cells (1976) (1)
- Preliminary Investigation of Focused Ultrasound-Facilitated Drug Delivery for the Treatment of Leptomeningeal Metastases (2018) (1)
- Increased ligand as a biomarker to guide optimal dosing of targeted antibody drugs to receptor tyrosine kinases (2005) (1)
- Fc Receptor Heterogeneity as a Marker for Lymphoid and Myeloid Cell Differentiation (1981) (1)
- Cancer Metastasis: Metronomic Chemotherapy for Treatment of Metastatic Disease: From Preclinical Research to Clinical Trials (2011) (1)
- FURTHER STUDIES OF ANTIGENIC COMPETITION (1971) (1)
- S14 Antiangiogenic therapy for breast cancer: What now? (2011) (1)
- Comment re: Preclinical Model of Spontaneous Melanoma Metastasis (2009) (1)
- 178PGENERATION OF A PLASMA MICRORNA (MIRNA) SIGNATURE PREDICTING RESPONSE TO METRONOMIC CHEMOTHERAPY (MC) FOR ADVANCED BREAST CANCER (ABC). (2014) (1)
- 217 POSTER Circulating levels of ligand as a potential biomarker for optimal dosing of targeted antibody drugs to the epidermal growth factor receptor (2006) (1)
- The Contribution of DNA Methylation to the Generation of Tumor Cell Heterogeneity, Tumor Progression and Metastasis (1989) (1)
- Recovery of Perfusion After Limb Ischemia Effects of Aging and Hypoxia-Inducible Factor-1 Activity on Angiogenic Cell Mobilization (2007) (1)
- Abstract IA29: Models of postsurgical early and late stage metastasis for improving preclinical adjuvant and metastatic therapy investigations (2013) (0)
- 75 INVITED Differential and Unexpected Impact of Adjuvant Versus Metastatic Antiangiogenic Therapy (2011) (0)
- Development of Orthotopic and Spontaneous Metastatic Human Tumor Xenograft Models for Experimental Therapeutics (2017) (0)
- 283 New preclinical models of metastatic colon cancer: towards bridging the gap between bench and bedside therapeutic outcomes (2010) (0)
- Analysis of acquired resistance to metronomic oral topotecan chemotherapy plus pazopanib after prolonged preclinical potent responsiveness in advanced ovarian cancer (2014) (0)
- Instructions for Authors (2004) (0)
- AModel of Postsurgical AdvancedMetastatic Breast Cancer More Accurately Replicates the Clinical Ef fi cacy of Antiangiogenic Drugs (2013) (0)
- erythroleukemic cells inflammatory mediators accelerating the expansion of murine The splenic microenvironment is a source of pro-angiogenesis / (2013) (0)
- 4. Advances in the Application of Metronomic Chemotherapy for the Treatment of Breast Cancer or Ovarian Cancer(Session 2 Oncology,Meet the Expert) (2009) (0)
- Abstract LB-079: Microbubble mediated focused ultrasound therapy enhances the antitumor potency and durability of anti-PD-L1 checkpoint blockade (2020) (0)
- 190 Sorafenib effectively controls early-stage hepatocellular carcinoma but not visceral metastases in a preclinical orthotopic transplant model (2010) (0)
- Lessons from the first ecancer symposium on angiogenesis in gastric cancer (2015) (0)
- Abstract 382: Platelets are implicated in the rapid host responses induced by cytotoxic chemotherapy which limit its anti-tumor efficacy (2010) (0)
- Temsirolimus (TEM) maintenance therapy after response of castration-resistant prostate cancer (CRPC) to docetaxel (TAX). (2012) (0)
- CLASSIFICATION O F T HYMUS-DERIVED A ND M ARROW-DERIVED LYMPHOCYTES B Y D EMONSTRATION O F T HEIR ANTIGEN-BINDING C HARACTERISTICS* (1972) (0)
- A tumor marker associated with metastatic potential. Abstr. (1980) (0)
- Tumor Cell Surface (ƒÀ1-4-Linked Galactose Binding to Lectin(s) on Microvascular Endothelial Cells and Contribution to Organ Colonization (2009) (0)
- Abstract 10: Evaluation of metronomic chemotherapy regimens in preclinical orthotopically implanted colon cancer models, and in patient-derived xenografts (2018) (0)
- The authors reply (2007) (0)
- Durability of cell line xenograft resection models to interrogate tumor micro-environment targeting agents (2019) (0)
- Metronomic anti-angiogenic combination therapy (2001) (0)
- Transforming Growth Factor 1 (TGFjJ1 ) Is an Autocrine Positive Regulator of Colon Carcinoma U9 Cells in Vivo as Shown by Transfection of a TGFI31 (1995) (0)
- Spontaneous Fusion InVivoBetween NormalHostand TumorCells: Possible Contribution toTumorProgression and Metastasis Studied withaLectin-Resistant MutantTumor (1983) (0)
- Impact of Endothelial Progenitor Cells on Tumor Angiogenesis and Outcome of Antiangiogenic Therapy: New Perspectives on an Ongoing Controversy (2010) (0)
- Correlation between metastatic potential of human melanoma cells and the distribution of integrin related receptors (1988) (0)
- Drug resistance of advanced cancers (2004) (0)
- Abstract 3142: Derivation and analysis of preclinical models of human her-2 positive breast cancer (2014) (0)
- A new method for the preparation of solid-phase immunoadsorbents. (1982) (0)
- Blood vessels and cancer (2019) (0)
- Abstract 1375: Contrasting effects of VEGF pathway inhibitors in primary and metastatic disease using perioperative neoadjuvant mouse models (2012) (0)
- Zubin Master (0)
- Targeting Oncogenes in Pediatric Malignancies (2003) (0)
- 460 Antiangiogenic drug alterations of the tumor microenvironment which can impact chemotherapy efficacy (2010) (0)
- Multicellular gastric cancer spheroids represent a valid model for pre-clinical testing of new therapeutic strategies (2001) (0)
- Consensus guidelines for the use and interpretation of angiogenesis assays (2018) (0)
- Abstract 4377: Metronomic oral prodrug of gemcitabine (LY2334737) causes antitumor effects with concomitant increase in intratumoral blood flow (2012) (0)
- - transformed Epithelial Cells and Fibroblasts ras Vascular Endothelial Growth Factor Up-Regulation in Oncogenes and Tumor Angiogenesis : Differential Modes of Updated (2000) (0)
- Rodent Tumor Models for Anti-cancer Drug Testing: An Overview (1998) (0)
- A preface from the new editors (2004) (0)
- Some guidelines for building a successful career in cancer research. (2003) (0)
- Altered metabolism of cyclophosphamide given in a low-dose metronomic manner does not account for eventual resistance (2005) (0)
- Therapeutics , Targets , and Chemical Biology Focused Ultrasound Delivers Targeted Immune Cells to Metastatic Brain Tumors (2013) (0)
- Cancer Stem Cells Promote Tumor Vascular Development - Response (2010) (0)
- Metronomic Antiangiogenic Chemotherapy: Questions and Answers (2008) (0)
- In vivo selection of human breast cancer cells that endogenously overexpress Her-2 (2015) (0)
- Reply to the Letter to the Editor on ‘Cost-opportunity analysis in clinical oncology: from the “wild far-west” to a correct integration of the disciplines, avoiding the “war of the worlds”’, by D. Tassinari et al. (Ann Oncol 2006; 17: 876) (2006) (0)
- Abstract IA22: Preclinical modeling of adjuvant and metastatic antiangiogenic therapy: Relevance for better predicting clinical outcomes (2015) (0)
- ErbB2/Her2-dependent downregulation of a cell death-promoting protein BLNK in breast cancer cells is required for 3D breast tumor growth (2022) (0)
- ADynamic De-Escalating Dosing Strategy to Determine the Optimal Biological Dose forAntiangiogenic Drugs 55 Commentary on Dowlati et al . , p . 7938 (2005) (0)
- Development of multicytokine resistanceʼ and multi-growth factor independence during human melanoma progression: 71 (1993) (0)
- Abstract 4249: NGR-TNF, a novel direct-acting vascular targeting agent, does not induce “cytokine-rebound” recruitment of pro-angiogenic bone-marrow derived cells (2011) (0)
- A phase II study of maintenance therapy with temsirolimus (TEM) after response to first-line docetaxel (TAX) chemotherapy in castration-resistant prostate cancer (CRPC). (2011) (0)
- [Metastatic dissemination of cancer cells]. (1991) (0)
- Preclinical impact of high dose intermittent antiangiogenic tyrosine kinase inhibitor pazopanib in intrinsically resistant tumor models (2018) (0)
- Course Announcement (2004) (0)
- Implementing subtype‐specific pre‐clinical models of breast cancer to study pre‐treatment aspirin effects (2022) (0)
- Oncogenic Regulation of Apoptosis in Transformed Intestinal Epithelial Cells (1997) (0)
- Tumor heterogeneity, invasion and metastasis. June 3-5, 1981, Saskatoon, Sask., Canada. (1982) (0)
- Course: Critical Issue in Tumor Microcirculation, Angiogenesis, and Metastasis: Biological Significane and Clinical Relevance (2004) (0)
- Late abstracts 186–187 (2005) (0)
- Eradication of established visceral metastases using syngeneic t cells sensitized against highly immunogenic tumor variants. Abstr. (1981) (0)
- Multimodal Imaging-Based Characterization of HER 2 + and Triple Negative Metastatic Breast Cancer Xenograft Models in Mice (2014) (0)
- Xenografts Determinant of Blood Vessel Patterning in Human Melanoma Vascular Endothelial Growth Factor Isoform Expression as a Updated (2002) (0)
- 180 Low-dose metronomic cyclophosphamide induced sustained hypoxia in human tumor xenografts, which can be exploited therapeutically by the combination with the hypoxic cell cytotoxin tirapazamine (2004) (0)
- Abstract C49: Combination treatment with metronomic cyclophosphamide and the EGFR monoclonal antibody nimotuzumab is efficacious and non‐toxic in a preclinical model of advanced triple negative breast cancer (2009) (0)
- Dual effects of different anti-angiogenic therapies over circulating endothelial progenitors and mature cells (2006) (0)
- Metronomic chemotherapy (MC) with UFT, cyclophosphamide (CTX) and celecoxib in patients with advanced gastrointestinal cancers: A clinical study with pharmacokinetic (PK) and pharmacodynamic (PD) evaluations (2008) (0)
- Abstract 863: Inhibition of breast cancer metastaticprogression by a novel uPAR targeted monoclonal antibody, ATN-658, correlateswith the uPAR expression. (2013) (0)
- 17 INVITED Metronomic antiangiogenic chemoterapy: recent preclinical and clinical advances (2006) (0)
- Abstract 3998: Metronomic gemcitabine plus neratinib effectively inhibits the growth of human Her-2 positive breast cancer cells intracranially implanted into immunodeficient mice (2023) (0)
- The Contribution of Circulating Endothelial Cells to Tumor Angiogenesis (2009) (0)
- Abstract 4381: The novel direct-acting vascular targeting agent NGR-TNF exertsin vivoantitumor activity by inducing endothelial and tumor cell death in the absence of proangiogenic bone-marrow derived cell recruitment (2012) (0)
- Phase I/II trial of metronomic chemotherapy with daily dalteparin and cyclophosphamide, twice-weekly methothrexate, and daily prednisone (DalCMP) as therapy for metastatic breast cancer (MBC). (2010) (0)
- Structure and function of murine TIMP gene. (1992) (0)
- Therapeutic impact of Nintedanib with paclitaxel and/or a PD-L1 antibody in preclinical models of orthotopic primary or metastatic triple negative breast cancer (2019) (0)
- 1 O - Experimental malignant conversion of early stage human melanoma cells: evidence for a dominant phenotype (1996) (0)
- On coalescent angiogenesis and the remarkable flexibility of blood vessels (2022) (0)
- Oncogenes and Tumor Angiogenesis : Differential Modes of Vascular Endothelial Growth Factor Up-Regulation in ras-transformed Epithelial Cells and Fibroblasts 1 (2000) (0)
- Abstract 3269: Recapitulating the BETH adjuvant breast cancer trial (NCT00625898) using clinically accurate orthotopic surgical resection models (2016) (0)
- Abstract 4124: Potent anti-tumor and metastatic breast cancer efficacy of bevacizumab with CRLX101, an investigational chemotherapy nanoparticle-drug conjugate that secondarily suppresses HIF-1α (2015) (0)
- Exploiting drug repositioning and the brain microenvironment to treat brain metastases. (2016) (0)
- Short Communication Neutralizing Antibodies against Epidermal Growth Factor and ErbB-2lneu Receptor Tyrosine Kinases Down-Regulate Vascular Endothelial Growth Factor Production by Tumor Cells in Vitro and in Vivo Angiogenic Implications for Signal Transduction Solid Tumors Therapy of (2007) (0)
- Abstract 1452: Examination of mechanisms involved in spontaneous melanoma metastasis to CNS (2010) (0)
- Endoglin and activin receptor-like kinase 1 heterozygous mice have a distinct pulmonary and hepatic angiogenic profile and response to anti-VEGF treatment (2013) (0)
- Advanced-Stage Lesions Inhibition of Human Melanoma Cell Lines Derived from Increased Resistance to Oncostatin M-induced Growth Updated (2006) (0)
- Isolation and Characterization of Spontaneous Wheat Germ Agglutinin-resistant Human Melanoma Mutants Displaying Remarkably Different Metastatic Profiles in Nude Mice 1 (2006) (0)
- Pre- and post-operative anti-PD-L1 plus anti-angiogenic therapies in mouse breast or renal cancer models of micro- or macro-metastatic disease (2018) (0)
- Anti-VEGF therapy reduces intestinal inflammation in Endoglin heterozygous mice subjected to experimental colitis (2014) (0)
- Insulin-like growth factor-1 (IGF-1) receptor-induced resistance to trastuzumab (Herceptin) in breast cancer (BC) xenografts in athymic mice can be measured using 111In-IGF-1-E3R (2007) (0)
- Derivation and analysis of preclinical models of human her-2 positive breast cancer (2014) (0)
- Macrophages eat their way into genetic control of immunity (1974) (0)
- Possible Involvementof Ca2+Mobilization and Protein Kinase C Activation in the Induction of Spontaneous Metastasis by Mouse Mammary Adenocarcinoma Cells1 (2006) (0)
- Possible Involvementof Ca 2 + Mobilization and Protein Kinase C Activation in the Inductionof Spontaneous Metastasis by Mouse Mammary Adenocarcinoma Cells 1 (2006) (0)
- Abstract 1254: Mechanistic interrogation of pre-treatment low dose aspirin effects in HER 2 positive breast cancer (2017) (0)
- Mechanisms of resistance to low-dose metronomic cyclophosphamide. (2006) (0)
- Expedition Inspiration Fund for Breast Cancer Research Meeting 2003 (2003) (0)
- Reply to “Limitations of combination anti-angiogenesis and chemotherapy” (2002) (0)
- Implications of Therapy-Induced Genetic/Epigenetic Modulations of Tumor Progression and Tumor Cell Heterogeneity for the Treatment of Cancer (1987) (0)
- New mouse models of melanoma metastasis and differences in brain tropism and metastatic growth pattern. (2012) (0)
- Induction of a malignant promonocyte-like cell line displaying spontaneous killer function. Abstr. (1980) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Robert S Kerbel?
Robert S Kerbel is affiliated with the following schools:
